HDAC1 and ovarian carcinoma: A global study of the relationship between the immunohistochemical expression of HDAC1 and the clinical and pathological data of patients with ovarian cancer revealed the maximum increase in nuclear expression in the samples obtained in patients with mucinous carcinoma, 80% with clear cell carcinoma, more than 70% with serous carcinoma, and 53% with endometrioid carcinoma [298], indicating a clear correlation of HDAC 1 levels with the prognosis.